Compare Adaptive Biotechnologies Corp (ADPT) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.23. Which is the better fit depends on your goals.
| ADPT | JEPQ | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $22.37 | $61.46 |
52-Week Low | $10.24 | $53.77 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
JEPQ trades at $60.16, up 1.3% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on the Nasdaq-100 to generate monthly income, with recent dividends of $0.64, $0.56, and $0.59. Media coverage highlights its role in retirement portfolios but notes performance trade-offs versus pure growth ETFs.
Outlook is mixed: strong income appeal for retirees balances against capped upside in tech rallies. Key risks include underperformance in bull markets and dependence on option premiums. Investors prioritize income over capital appreciation with this strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
